Join our daily newsletter At The Bell to receive exclusive market insights
Chimeric Therapeutics (ASX:CHM) has reported one leukaemia patient has shown a complete response in its latest drug trial – in other words, for now, that patient is cancer-free.
This latest breakthrough – which could bode well for Chimeric shareholders, given the stock is currently suspended – comes on the back of a trial using a combination of ‘CORE-NK‘ and Vactosertib in advanced cancer patients.
‘CORE-NK’ takes its name from Natural Killer (NK) cells which “are part of our innate immune system,” according to the company’s website. A previous trial found more success combining it with Vactosertib.
This is the first round of trials to ever mix that drug with NK cell treatments; the trial is being undertaken at the UH Seidman Cancer Center in Ohio, USA.
“We are very happy to report that one study subject with advanced Acute Myelogenous Leukemia (AML) experienced a Complete Response at Day 28 after starting treatment with the CHM CORE- NK + Vactosertib combination,” Chimeric COO Dr. Rebecca McQualter said.
“As the study continues to enrol subjects with advanced cancer, we are pleased to see the clinical combination can be delivered safely.”
“The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. Three patients are currently enrolled in the Phase 1b study with the goal to enrol 12 patients,” the company wrote on Monday.
CHM last traded at 1.4cps.
Join the discussion: See what HotCopper users are saying about Chimeric Therapeutics and be part of the conversations that move the markets.
